{"id":4260,"date":"2026-11-11T19:00:00","date_gmt":"2026-11-11T23:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4260"},"modified":"2026-11-12T20:57:27","modified_gmt":"2026-11-13T00:57:27","slug":"eli-radiopharma-closes-nearly-rmb-400-million-series-a","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4260","title":{"rendered":"Eli Radiopharma Closes Nearly RMB 400 Million Series A"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Eli_Radiopharma_Deal_and_Financing-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4281\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Eli_Radiopharma_Deal_and_Financing-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Eli_Radiopharma_Deal_and_Financing-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Eli_Radiopharma_Deal_and_Financing-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Eli_Radiopharma_Deal_and_Financing-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Eli_Radiopharma_Deal_and_Financing.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Hangzhou Eli Radiopharma<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Series A financing (nearly RMB 400 million)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Radiopharmaceutical<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Undisclosed preclinical programs<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Undisclosed<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Oncology; neurological disease<\/p>\n<h4>Summary<\/h4>\n<p>Hangzhou Eli Radiopharma disclosed a newly closed Series A of nearly RMB 400 million. The company-origin English release was November 11 at 19:00 ET; Chinese reporting dated November 12 locally. This is new capital, not a clinical readout.<\/p>\n<p>Huagai Capital led and Bayland Capital co-led; both new and existing investors participated. Proceeds are intended for preclinical work, IND submissions, early development and platform buildout. Several programs are said to approach IND, but targets, isotopes, trial designs, runway and transaction terms were not disclosed.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> a sizeable round can carry a Chinese radiopharma platform across first IND and manufacturing setup. Support: named investors and stated development use. Against: no disclosed asset-level validation or human dosimetry.<\/p>\n<p><strong>Interpretation B:<\/strong> capital may be absorbed by isotope supply, chelation chemistry, radiochemistry quality control and center logistics before a differentiated clinical signal appears. Support: these are core platform constraints. Against: integrated diagnostic and therapeutic work could de-risk patient selection. The first IND, target expression, biodistribution, dosimetry, isotope sourcing, GMP reproducibility, IP position and financing runway would test platform value. Domestic trial results may require separate global regulatory bridging.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Eli develops targeted radiopharmaceutical diagnostics and therapeutics for oncology and neurological disease. The mechanism is a targeting ligand delivering a diagnostic or therapeutic radionuclide; specific lead constructs are undisclosed.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified: company-supplied syndication and original Chinese-language disclosure agree on amount, stage and leads.<\/li>\n<li>Missing: asset codes, radionuclides, valuation and runway.<\/li>\n<li>No inference that the entire amount has already been deployed.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The round funds an important move toward first clinical testing, while specific assets and isotope supply remain undisclosed. IND acceptance, dosimetry and reproducible manufacturing will determine whether the platform differentiates.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: neutral. Confidence in Facts: high. Confidence in Interpretation: low-moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou Eli Radiopharma disclosed a newly closed Series A of nearly RMB 400 million. The company-origin English release was November 11 at 19:00 ET; Chinese reporting dated November 12 locally. This is new capital,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4281,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[1457,829,879],"class_list":["post-4260","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-eli-radiopharma","tag-radiopharmaceuticals","tag-series-a"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4260"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4260\/revisions"}],"predecessor-version":[{"id":4287,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4260\/revisions\/4287"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4281"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}